DRD4; FFAR1; FFAR4; ADORA3; ADORA2A; ADORA1; ADRA2B; | |
TSHR; NPSR1; CXCR1; | |
PLA2G1B; TDP1; CDA; FAAH; RECQL; P4HB; TERT; MTOR; ADK; PIK3R1; GLO1; DAO; HPGD; MPO; AKR1B1; HSD17B10; ALOX15; ALDH1A1; HSD17B2; ALOX12; NOX4; TNKS; PARP1; TNKS2; PYGL; POLB; CD38; | |
ACHE; GAA; | |
TRPV1; | |
NEK6; AKT1; MET; CAMK2B; CSNK2A1; DAPK1; AXL; FLT3; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; MAPK1; PIM1; NUAK1; ALK; NEK2; KDR; PKN1; | |
CA3; CA14; CA7; CA9; CA6; CA4; CA2; CA12; CA1; CA5A; | |
NR1H4; | |
PPARA; PPARG; PPARD; | |
KDM4E; | |
MAOA; ALOX5; DHFR; PTGS1; XDH; | |
MMP13; MMP12; MMP3; MMP2; MMP9; | |
BACE1; | |
TLR2; | |
STAT6; HIF1A; NFKB1; TP53; | |
SLC28A2; SLC28A1; SLC28A3; SLCO1B3; SLCO1B1; | |
ABCC1; ABCG2; | |
LMNA; FABP5; FABP2; FABP4; MAPT; PMP22; FABP3; APP; TTR; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | DAO | D-amino-acid oxidase | P14920 | CHEMBL5485 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | DHFR | Dihydrofolate reductase | P00374 | CHEMBL202 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | PMP22 | Peripheral myelin protein 22 | Q01453 | CHEMBL1293298 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.420E-12 | 4.354E-10 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, XDH |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.097E-11 | 2.808E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.434E-11 | 7.789E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.778E-11 | 1.040E-08 | CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.299E-11 | 1.142E-08 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.166E-11 | 1.486E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.925E-10 | 3.709E-08 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, CDA, GLO1, L3MBTL1, MMP12, MMP13, MMP2, MMP3, MMP9, NR1H4, PARP1, PPARA, PPARD, PPARG, TNKS, TP53 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.027E-10 | 3.839E-08 | ABCG2, ACHE, ADORA2A, AKT1, ALK, APP, CAMK2B, CD38, CDA, CSNK2A1, DAPK1, DRD4, FLT3, HPGD, IGF1R, KDR, L3MBTL1, MAPK1, MAPT, MET, MMP9, MTOR, NFKB1, PARP1, PPARG, PYGL, SMN1, SMN2, STAT6, TERT, TP53, TRPV1, TTR, XDH |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 9.725E-10 | 1.491E-07 | ADORA1, ADORA2A, AURKB, CA2, CA7, CD38, HIF1A, KDR, MAPK1, NEK2, NPSR1, NR1H4, PARP1, PLA2G1B, SRC, TNKS, TNKS2, TRPV1 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.394E-09 | 2.011E-07 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, MTOR, PKN1, TNKS |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.465E-09 | 2.072E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.787E-09 | 8.850E-07 | CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 7.180E-09 | 9.288E-07 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, MTOR, NEK6, PKN1, SRC, TNKS |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.834E-08 | 2.147E-06 | AKT1, HIF1A, LMNA, MTOR, P4HB, PPARD, SRC, TERT, TP53 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.873E-08 | 2.181E-06 | ADORA2A, AURKB, CA2, CA7, HIF1A, MAPK1, NEK2, NPSR1, NR1H4, PLA2G1B, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 2.363E-08 | 2.652E-06 | ABCC1, ABCG2, ADK, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, MTOR, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53, TRPV1 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 3.455E-08 | 3.706E-06 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B, TLR2 |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 4.431E-08 | 4.573E-06 | ADORA1, ADORA2A, CYP19A1, FFAR4, NFKB1, NR1H4, PPARA, PPARD, PPARG |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 5.172E-08 | 5.238E-06 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.578E-07 | 1.432E-05 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, MTOR, NEK2, NEK6, NUAK1, PIM1, PKN1 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 3.393E-07 | 2.920E-05 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B, TRPV1 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 7.560E-07 | 6.097E-05 | ADORA1, ADORA2A, CA2, CA7, KDR, NPSR1, PARP1, PLA2G1B, SRC, TRPV1 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.744E-06 | 1.283E-04 | ABCC1, ADORA1, ADORA2A, ADORA3, ADRA2B, ALK, APP, AXL, BACE1, DRD4, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPSR1, SLC28A1, SLC28A2, SLC28A3, SLCO1B1, SLCO1B3, TLR2, TRPV1, TSHR |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 2.136E-06 | 1.520E-04 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.376E-06 | 1.680E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.516E-06 | 1.756E-04 | ALOX12, ALOX15, ALOX5, HPGD |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.622E-06 | 1.819E-04 | ABCC1, ADORA1, CA2, CA4, CA9, HPGD, SLCO1B1, SLCO1B3, TSHR |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 3.274E-06 | 2.207E-04 | CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 4.189E-06 | 2.764E-04 | AKT1, DHFR, HIF1A, TERT |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 4.730E-06 | 3.056E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 6.446E-06 | 4.022E-04 | MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 7.234E-06 | 4.450E-04 | AKT1, FFAR1, HIF1A, NOX4, NR1H4, PIK3R1, PPARG, PYGL |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 8.074E-06 | 4.876E-04 | CYP1A1, POLB, PPARG, TP53 |
BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 8.240E-06 | 4.876E-04 | CYP1A1, CYP2A6, CYP2D6 |
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 8.240E-06 | 4.876E-04 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 8.304E-06 | 4.887E-04 | ADORA1, ADORA2A, ADORA3, APP, CYP1B1, FABP3, LMNA, NOX4, PKN1, PMP22, PPARD, PPARG, TERT, TLR2, TP53, XDH |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 9.821E-06 | 5.703E-04 | HPGD, MMP2, MMP9, TERT |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 1.228E-05 | 7.001E-04 | ALOX15, GSK3B, MAPT, MET, MMP3, MTOR, PARP1, SRC, TP53 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.311E-05 | 7.367E-04 | AKT1, APP, CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4, PPARG, SRC, TRPV1 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.666E-05 | 9.112E-04 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.674E-05 | 9.112E-04 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 1.699E-05 | 9.202E-04 | ADORA1, ALOX12, APP, AXL, CD38, FFAR4, GSK3B, HIF1A, LMNA, MTOR, NFKB1, NR1H4, PIK3R1, PMP22, PPARD, PPARG, PTK2, TERT, TLR2, XDH |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.697E-05 | 9.202E-04 | CAMK2B, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, FAAH, HSD17B2, MTOR, NOX4, PTGS1, SLC28A3 |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 1.960E-05 | 1.035E-03 | ADORA2A, APP, MAPT |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.960E-05 | 1.035E-03 | ADORA1, ADORA2A, ADORA3 |
MF | GO:0005488; binding | GO:0032052; bile acid binding | 1.960E-05 | 1.035E-03 | NR1H4, PLA2G1B, PYGL |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 2.300E-05 | 1.182E-03 | PARP1, SRC, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 2.300E-05 | 1.182E-03 | APP, GSK3B, IGF1R, PARP1 |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 2.758E-05 | 1.397E-03 | ADORA2A, AKT1, CYP1B1, DAPK1, GSK3B, HPGD, MAPT, MMP9, NOX4, PPARG, SRC, TP53, TRPV1, XDH |
BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 2.787E-05 | 1.408E-03 | PPARG, SRC, TP53 |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 3.288E-05 | 1.638E-03 | ADRA2B, ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B |
BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 3.438E-05 | 1.696E-03 | ADORA1, CD38, PARP1, SRC, TNKS, TNKS2, TRPV1 |
BP | GO:0007610; behavior | GO:0007610; behavior | 3.442E-05 | 1.696E-03 | ADORA2A, ALK, APP, DRD4, GAA, HIF1A, MAPK1, MAPT, MTOR, PPARA, TLR2, TP53, TRPV1 |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 3.510E-05 | 1.721E-03 | APP, CDK1, MAPK1, PARP1, PIK3R1, TLR2 |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 3.510E-05 | 1.721E-03 | ADORA1, ADORA2A, DRD4, PPARA, PPARG, TP53 |
BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 3.892E-05 | 1.863E-03 | SLC28A2, SLC28A3 |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.892E-05 | 1.863E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0019858; cytosine metabolic process | 3.892E-05 | 1.863E-03 | CDA, MAPK1 |
MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 3.892E-05 | 1.863E-03 | SLC28A1, SLC28A3 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.892E-05 | 1.863E-03 | ALOX12, ALOX15 |
MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 3.892E-05 | 1.863E-03 | SLC28A2, SLC28A3 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 3.990E-05 | 1.897E-03 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 4.044E-05 | 1.910E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 4.600E-05 | 2.140E-03 | CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 4.855E-05 | 2.245E-03 | AXL, MET, MTOR, NOX4, PIK3R1, PTK2, SRC |
CC | GO:0044464; cell part | GO:0005829; cytosol | 4.965E-05 | 2.291E-03 | ADK, AKR1B1, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CDA, CDK1, CSNK2A1, DAO, DHFR, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HIF1A, HPGD, LMNA, MAPK1, MAPT, MTOR, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PPARG, PTK2, PYGL, SMN1, SMN2, SRC, STAT6, TNKS, TNKS2, TP53, TRPV1, XDH |
BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 5.077E-05 | 2.337E-03 | ALOX5, CDA, CXCR1, FABP5, GAA, MAPK1, MMP9, MPO, NFKB1, PYGL, TLR2, TTR |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 5.430E-05 | 2.458E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0065007; biological regulation | GO:0051100; negative regulation of binding | 5.497E-05 | 2.473E-03 | AURKB, CYP2D6, GSK3B, MET, NEK2, PPARA, TNKS |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 5.875E-05 | 2.616E-03 | ADRA2B, AKT1, MTOR, SRC |
BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 6.550E-05 | 2.841E-03 | ADORA2A, CA2, CA7 |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 6.719E-05 | 2.903E-03 | ADRA2B, AKT1, AXL, MAPK1, PIK3R1, SRC |
BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 6.751E-05 | 2.905E-03 | AKT1, HIF1A, NFKB1, PPARA, SRC |
BP | GO:0023052; signaling | GO:0032024; positive regulation of insulin secretion | 6.751E-05 | 2.905E-03 | CD38, FFAR1, HIF1A, NR1H4, PPARD |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 6.806E-05 | 2.923E-03 | ADORA1, ADORA2A, AXL, HIF1A, NFKB1, P4HB, PIK3R1, PPARD, PPARG, TLR2, TP53, TTR |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 7.728E-05 | 3.261E-03 | ADK, AKR1B1, AKT1, ALOX5, AURKB, CAMK2B, CDK1, CSNK2A1, FABP5, GSK3B, HIF1A, HPGD, L3MBTL1, LMNA, MAPK1, MTOR, NEK2, NEK6, NFKB1, NR1H4, NUAK1, PARP1, PIM1, PKN1, POLB, PPARA, PPARD, PPARG, RECQL, SMN1, SMN2, SRC, STAT6, TERT, TNKS, TP53 |
BP | GO:0065007; biological regulation | GO:0051101; regulation of DNA binding | 7.806E-05 | 3.288E-03 | MMP9, NEK2, PARP1, PPARA, PPARG, TNKS |
BP | GO:0009987; cellular process | GO:0045742; positive regulation of epidermal growth factor receptor signaling pathway | 8.246E-05 | 3.433E-03 | ADORA1, ADRA2B, AKT1, MMP9 |
MF | GO:0005488; binding | GO:0001221; transcription cofactor binding | 8.246E-05 | 3.433E-03 | NEK6, PPARA, TERT, TP53 |
BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 8.797E-05 | 3.628E-03 | FLT3, HIF1A, KDR, L3MBTL1, MAPK1, PKN1, POLB |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 8.883E-05 | 3.656E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
BP | GO:0032501; multicellular organismal process | GO:0044057; regulation of system process | 1.026E-04 | 4.135E-03 | ADORA1, ADORA2A, ADORA3, ADRA2B, AKT1, CAMK2B, CD38, GAA, LMNA, MTOR, PARP1, TRPV1 |
BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 1.033E-04 | 4.156E-03 | TERT, TNKS, TNKS2 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.150E-04 | 4.521E-03 | AXL, CDK1, CSNK2A1, FLT3, PPARG |
BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 1.163E-04 | 4.521E-03 | APP, TLR2 |
BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.163E-04 | 4.521E-03 | SLC28A1, SLC28A3 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.163E-04 | 4.521E-03 | CYP2D6, CYP3A4 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.163E-04 | 4.521E-03 | CA2, CA7 |
BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.163E-04 | 4.521E-03 | SLC28A1, SLC28A3 |
MF | GO:0005488; binding | GO:0051219; phosphoprotein binding | 1.150E-04 | 4.521E-03 | MAPK1, MTOR, PIK3R1, SRC, TRPV1 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.163E-04 | 4.521E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.163E-04 | 4.521E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.163E-04 | 4.521E-03 | ALOX12, ALOX15 |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.163E-04 | 4.521E-03 | ADORA1, ADORA2A |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 1.224E-04 | 4.715E-03 | ALOX15, MTOR, PPARA, PPARD, TP53 |
BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.224E-04 | 4.715E-03 | GSK3B, MAPT, MTOR, PARP1, TP53 |
MF | Unclassified; | GO:0004872; receptor activity | 1.253E-04 | 4.813E-03 | ADORA1, ADORA2A, ADORA3, ADRA2B, ALK, AXL, CXCR1, DRD4, FFAR1, FFAR4, FLT3, HPGD, IGF1R, KDR, MET, NPSR1, NR1H4, PPARA, PPARD, PPARG, TLR2, TRPV1, TSHR |
CC | GO:0044464; cell part | GO:0030673; axolemma | 1.265E-04 | 4.850E-03 | ADORA1, ADORA2A, MAPT |
BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 1.301E-04 | 4.967E-03 | CAMK2B, GSK3B, MAPK1, MAPT, MTOR |
BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 1.305E-04 | 4.967E-03 | ADORA1, ADORA2A, ADRA2B, AKT1, CD38, PPARD |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.382E-04 | 5.230E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0051179; localization | GO:0046326; positive regulation of glucose import | 1.497E-04 | 5.572E-03 | AKT1, NR1H4, PIK3R1, TERT |
BP | GO:0002376; immune system process | GO:0001774; microglial cell activation | 1.529E-04 | 5.615E-03 | MAPT, TLR2, TRPV1 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 1.529E-04 | 5.615E-03 | CYP1A1, PPARD, PPARG |
BP | GO:0008152; metabolic process | GO:0031998; regulation of fatty acid beta-oxidation | 1.529E-04 | 5.615E-03 | AKT1, MTOR, PPARA |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.529E-04 | 5.615E-03 | AURKB, CDK1, PKN1 |
BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 1.533E-04 | 5.618E-03 | ADRA2B, AKT1, APP, AXL, CA2, CAMK2B, HIF1A, KDR, MAPT, MTOR, NFKB1, PARP1, PPARD, PPARG, TERT, TLR2 |
BP | GO:0009987; cellular process | GO:1901215; negative regulation of neuron death | 1.719E-04 | 6.238E-03 | ADORA2A, AKT1, AXL, GSK3B, HIF1A, PPARA, TERT |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.790E-04 | 6.442E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0048714; positive regulation of oligodendrocyte differentiation | 1.827E-04 | 6.489E-03 | MTOR, PPARG, TLR2 |
BP | GO:0050896; response to stimulus | GO:0031000; response to caffeine | 1.827E-04 | 6.489E-03 | ADORA2A, PPARG, TP53 |
CC | GO:0044464; cell part | GO:0034774; secretory granule lumen | 1.914E-04 | 6.733E-03 | ALOX5, APP, CDA, FABP5, MAPK1, MPO, NFKB1, PYGL, TTR |
BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 1.924E-04 | 6.757E-03 | AKT1, APP, CDK1, DAPK1, GSK3B, MAPT, PPARG, PTK2, SRC, XDH |
BP | GO:0008152; metabolic process | GO:0042136; neurotransmitter biosynthetic process | 1.951E-04 | 6.823E-03 | ACHE, AKT1, CYP1B1, DHFR |
MF | GO:0005488; binding | GO:0042562; hormone binding | 1.952E-04 | 6.823E-03 | ACHE, ALDH1A1, IGF1R, PIK3R1, TTR |
BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 1.984E-04 | 6.913E-03 | ABCG2, APP, CA12, CA2, CA7, CD38, DRD4, HIF1A, MAPK1, NPSR1, PLA2G1B, TP53, TRPV1 |
BP | GO:0009987; cellular process | GO:0010639; negative regulation of organelle organization | 2.051E-04 | 7.134E-03 | AKT1, LMNA, MAPT, MET, NEK2, PARP1, SRC, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.122E-04 | 7.311E-03 | IGF1R, KDR, PTK2, SRC |
BP | Unclassified; | GO:1905953; negative regulation of lipid localization | 2.122E-04 | 7.311E-03 | AKT1, NFKB1, PPARA, PPARG |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 2.316E-04 | 7.819E-03 | TNKS, TNKS2 |
BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 2.316E-04 | 7.819E-03 | APP, TLR2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.316E-04 | 7.819E-03 | CYP1A1, CYP1A2 |
BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 2.329E-04 | 7.851E-03 | ABCG2, APP, CA2, CA7, CD38, DRD4, HIF1A, MAPK1, NPSR1, PLA2G1B, TP53, TRPV1 |
BP | GO:0002376; immune system process | GO:0002683; negative regulation of immune system process | 2.398E-04 | 8.046E-03 | ADORA1, ADORA2A, ALOX15, AXL, CYP19A1, MMP12, PIK3R1, PKN1, PPARG, STAT6 |
MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 2.497E-04 | 8.325E-03 | NR1H4, PPARA, PPARD, PPARG |
MF | GO:0005488; binding | GO:0019901; protein kinase binding | 2.775E-04 | 9.100E-03 | AKT1, GSK3B, HIF1A, MAPK1, MTOR, NEK6, PARP1, PIK3R1, PKN1, PTK2, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0090407; organophosphate biosynthetic process | 2.784E-04 | 9.114E-03 | ACHE, ADK, ADORA2A, ALOX15, CSNK2A1, DHFR, MAPK1, PIK3R1, PLA2G1B, PPARD, PYGL |
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 2.933E-04 | 9.530E-03 | ADORA1, ADORA2A, ADORA3, ADRA2B, ALK, AXL, CXCR1, DRD4, FFAR1, FFAR4, FLT3, HPGD, IGF1R, KDR, MET, NPSR1, PPARG, TRPV1, TSHR |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.862E-19 | 5.279E-16 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.412E-14 | 8.539E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, DHFR |
MF | GO:0005488; binding | GO:0020037; heme binding | 6.336E-14 | 2.999E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, MPO, NOX4, PTGS1, SRC |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.321E-13 | 5.642E-11 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.690E-13 | 6.944E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, NOX4 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 8.435E-19 | 1.636E-16 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.561E-12 | 1.514E-10 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; MMP9; PTK2; MTOR; IGF1R; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.756E-10 | 1.337E-08 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; MTOR; PTK2; IGF1R; AKT1; MAPK1; PPARG; MET; TP53; PPARD |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 7.855E-11 | 5.080E-09 | CYP2C9; APP; CYP2C8; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS1 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.832E-09 | 5.924E-08 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; MTOR; PPARD |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.656E-09 | 1.013E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS1 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.480E-10 | 1.350E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.967E-08 | 3.469E-07 | CDA; PLA2G1B; MAOA; ALOX15; ADK; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; ALOX5; HSD17B2; CD38; XDH; GAA; DHFR; CYP2C9; CYP2C8; CYP2A6; DAO; CYP1A2; ALDH1A1; CYP1A1 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.877E-09 | 1.668E-07 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A; MTOR |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 8.728E-09 | 1.881E-07 | CYP2C9; CYP2C8; CYP2A6; MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.251E-08 | 2.426E-07 | HPGD; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 6.667E-08 | 9.238E-07 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1; MTOR; IGF1R |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.537E-07 | 1.754E-06 | GSK3B; PIK3R1; PTK2; NFKB1; MTOR; IGF1R; KDR; AKT1; MAPK1; PKN1; TP53; MET; TLR2 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 5.572E-08 | 8.315E-07 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; MTOR; PTK2 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.297E-07 | 1.572E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; MTOR; IGF1R |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.485E-08 | 5.634E-07 | CYP2C9; CYP2C8; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.593E-07 | 2.396E-06 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.297E-07 | 1.572E-06 | CYP2C9; CYP2C8; CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.092E-07 | 2.029E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; MTOR; IGF1R |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 5.969E-07 | 4.825E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A; MTOR |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.970E-07 | 2.011E-06 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.916E-07 | 2.571E-06 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 6.787E-07 | 5.267E-06 | ABCC1; ADORA3; ADORA1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.637E-07 | 1.764E-06 | DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.650E-06 | 1.143E-05 | AKT1; PPARG; PIK3R1; TP53; NFKB1; MTOR; IGF1R |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.449E-06 | 2.158E-05 | CAMK2B; ADORA2A; ADORA1; AKT1; MAPK1; PIK3R1; PPARA; NFKB1; TSHR |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.534E-07 | 4.668E-06 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 3.897E-06 | 2.363E-05 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.098E-06 | 8.191E-06 | FABP4; ADORA1; AKT1; PIK3R1; TSHR; PTGS1 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.457E-06 | 2.493E-05 | GSK3B; AKT1; PIK3R1; PYGL; PPARA; NFKB1; MTOR |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.832E-06 | 1.225E-05 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 8.423E-06 | 4.416E-05 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.839E-05 | 8.918E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.355E-06 | 9.736E-06 | CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 4.497E-06 | 2.493E-05 | AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.882E-06 | 2.631E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.651E-05 | 8.213E-05 | GSK3B; AKT1; MAPK1; PIK3R1; PPARA; TP53; NFKB1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.302E-05 | 1.039E-04 | PARP1; LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 1.908E-05 | 9.030E-05 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; TLR2 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.198E-05 | 1.349E-04 | GSK3B; CSNK2A1; CDK1; AKT1; CD38; PIK3R1; TP53; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.497E-06 | 2.493E-05 | SLCO1B1; CA2; SLCO1B3; NR1H4; CYP3A4; ABCG2 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.434E-05 | 1.417E-04 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 4.359E-05 | 1.726E-04 | ADORA2A; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.066E-05 | 1.346E-04 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 7.289E-05 | 2.668E-04 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 5.552E-05 | 2.071E-04 | MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 8.219E-05 | 2.797E-04 | ABCC1; PIM1; CYP1B1; MAPK1; TP53; MMP9; MET; NFKB1; MTOR |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.544E-05 | 7.884E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.226E-05 | 1.028E-04 | ALK; AKT1; MAPK1; PIK3R1; TP53 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 8.213E-05 | 2.797E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.526E-04 | 7.780E-04 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 3.123E-05 | 1.346E-04 | AKT1; MAPK1; PIK3R1; HIF1A; MTOR |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.019E-04 | 6.318E-04 | GSK3B; AKT1; MAPK1; PIK3R1; PYGL; MTOR |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 8.067E-05 | 2.797E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.964E-05 | 1.888E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 8.067E-05 | 2.797E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.664E-05 | 1.481E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 3.234E-04 | 9.653E-04 | CDK1; AKT1; MAPK1; PIK3R1; IGF1R |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 4.964E-05 | 1.888E-04 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 3.234E-04 | 9.653E-04 | CAMK2B; SRC; ALOX12; TRPV1; PIK3R1 |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 5.395E-04 | 1.495E-03 | ADORA3; ADORA1; AKT1; MAPK1; PIK3R1; ADRA2B |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.718E-04 | 1.093E-03 | AKT1; MAPK1; PIK3R1; HIF1A; MTOR |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.567E-04 | 1.521E-03 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 4.255E-04 | 1.214E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 4.644E-04 | 1.306E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 5.735E-04 | 1.545E-03 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.757E-04 | 5.588E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 4.255E-04 | 1.214E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 7.539E-04 | 1.950E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1; TLR2 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 9.929E-04 | 2.408E-03 | POLB; GSK3B; TERT; AKT1; PIK3R1; TP53; NFKB1 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 8.610E-05 | 2.880E-04 | CSNK2A1; SRC; MAPK1; MET; IGF1R |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.495E-03 | 3.453E-03 | ADORA2A; ADORA3; ADORA1; TRPV1; ADRA2B; DRD4; TSHR |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 8.799E-04 | 2.188E-03 | SRC; AKT1; MAPK1; PIK3R1; PTGS1 |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 9.466E-04 | 2.325E-03 | AKT1; PPARG; PIK3R1; MTOR; IGF1R |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.252E-03 | 2.961E-03 | AKT1; MAPK1; PPARG; PIK3R1; NFKB1 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.729E-03 | 3.899E-03 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.130E-03 | 2.706E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 2.261E-03 | 4.951E-03 | GSK3B; AKT1; PIK3R1; PPARA; NFKB1 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.729E-03 | 3.899E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.838E-03 | 4.099E-03 | CXCR1; AKT1; MAPK1; PIK3R1; MTOR |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.751E-03 | 5.865E-03 | CAMK2B; SRC; CD38; MAPK1; PIK3R1 |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 2.751E-03 | 5.865E-03 | PIM1; AKT1; STAT6; PIK3R1; MTOR |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 4.256E-03 | 8.692E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 5.375E-03 | 1.086E-02 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.070E-02 | 3.492E-02 | CXCR1; SRC; KDR; MET; IGF1R |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.255E-02 | 2.296E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.950E-02 | 3.348E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 6.657E-03 | 1.318E-02 | CAMK2B; CDK1; MAPK1; IGF1R |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 8.725E-03 | 1.627E-02 | AKT1; MAPK1; PIK3R1; IGF1R |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 5.758E-03 | 1.152E-02 | MMP2; PIK3R1; MMP9; PTK2 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 7.440E-03 | 1.429E-02 | GSK3B; MAPK1; MET; PTK2 |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 3.313E-03 | 6.838E-03 | CAMK2B; AKT1; PYGL; PPARA |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 2.271E-03 | 4.951E-03 | CAMK2B; SRC; MMP2; MAPK1 |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 3.197E-03 | 6.669E-03 | PIK3R1; NFKB1; PTK2; TLR2 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.284E-02 | 3.820E-02 | CAMK2B; GSK3B; MAPK1 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.889E-02 | 3.273E-02 | AKT1; MAPK1; PIK3R1 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.288E-03 | 3.009E-03 | SRC; PIK3R1; MET; PTK2 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 8.589E-04 | 2.164E-03 | AKT1; PPARA; NFKB1; MTOR |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 6.120E-04 | 1.626E-03 | AKT1; PIK3R1; MTOR; IGF1R |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 2.054E-02 | 3.492E-02 | CA2; PLA2G1B; CD38 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.889E-02 | 3.273E-02 | CSNK2A1; PARP1; NFKB1 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.633E-02 | 2.906E-02 | SRC; CDK1; MAPK1 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 7.700E-04 | 1.965E-03 | CXCR1; SRC; MET; NFKB1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.536E-02 | 2.759E-02 | MAPK1; PKN1; NFKB1 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 9.877E-03 | 1.825E-02 | MAPK1; NFKB1; TLR2 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 8.134E-03 | 1.547E-02 | AKT1; MAPK1; PIK3R1 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 7.183E-03 | 1.393E-02 | SRC; MAPK1; NFKB1 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 7.183E-03 | 1.393E-02 | STAT6; NFKB1; TLR2 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.709E-04 | 5.526E-04 | CDA; CYP2A6; CYP3A4; XDH |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 9.844E-05 | 3.237E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 3.034E-02 | 4.865E-02 | AKT1; PIK3R1 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 3.064E-03 | 6.460E-03 | MAPK1; PIK3R1; MTOR |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.911E-02 | 4.706E-02 | ABCC1; ABCG2 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.325E-02 | 3.855E-02 | MAPK1; PIK3R1 |
hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 2.553E-02 | 4.162E-02 | FABP2; PLA2G1B |
hsa00260 | Glycine, serine and threonine metabolism_Homo sapiens_hsa00260 | 2.438E-02 | 4.008E-02 | DAO; MAOA |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 7.036E-04 | 1.845E-03 | MAPK1; PPARG; TP53 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.414E-02 | 2.563E-02 | GAA; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.696E-02 | 2.991E-02 | POLB; PARP1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 8.452E-03 | 1.592E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.141E-06 | 1.385E-05 | CYP2A6; CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; PARP1 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; ADK |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12; PPARD |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; ADORA2A |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; MMP12; TRPV1; ADORA2A; ADORA1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5 |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; TRPV1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2; ADORA1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; TLR2; CDA; MTOR; FLT3; CA9; MMP2; DHFR; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; KDR; KDR; KDR |
C00-D49: Neoplasms | Solid tumors | NA | MTOR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; GSK3B; ADORA1; PPARG |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR |
NA: NA | Dyslipidemia | NA | PPARD |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
NA: NA | Rheumatold arthritis | NA | PTGS1 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
C00-D49: Neoplasms | Breast cancer | C50 | TERT; CYP19A1; FLT3; FLT3; CA9; IGF1R; CDK1; KDR; KDR; KDR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; FAAH; CYP3A4 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DAO; MAPT; ACHE; ADORA1 |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; MTOR; DHFR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; MTOR; IGF1R; IGF1R; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; TRPV1; PTGS1 |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2B |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | KDR; APP |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADORA3; ADORA2A; ADORA1; CA1; CA1 |
NA: NA | Geographic retinal atrophy | NA | APP |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; TRPV1; PTGS1; ADORA2A; ADORA1; ADRA2B |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; ADORA1 |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ADORA2A |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; MTOR; MMP12; PTGS1; FAAH |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3; PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1 |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
NA: NA | GIST | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH; PPARG |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; PTGS1 |
C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; ADORA2A; ADORA1 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; MTOR; ADK; ACHE; TRPV1; TRPV1; PTGS1; IGF1R; ADORA2A; CDK1; FAAH |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TLR2; TERT; MTOR; FLT3; MMP2; KDR |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; NFKB1; PPARG; PPARG; PPARD |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; TRPV1 |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2; PARP1; KDR; KDR; KDR; KDR |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; AURKB; TP53; TP53 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1 |
NA: NA | Hepatitis C virus infection | NA | ADORA3 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; APP |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; MTOR; CA9; HIF1A |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARG; PPARD; PPARD |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; MMP3; DHFR |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; GSK3B; PPARG; PPARG; APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; TLR2; CSNK2A1; MTOR; FLT3; FLT3; CA9; MMP2; ACHE; DHFR; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; PARP1; CD38; TP53; CA1; KDR; APP |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; PARP1; KDR; KDR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; XDH |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; PTGS1 |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; CD38; TP53 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
NA: NA | Coronary artery restenosis | NA | MTOR |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ADORA1 |
C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; MTOR; MTOR; SRC; IGF1R; CD38 |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
NA: NA | Esophagus sensitivity | NA | TRPV1 |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12; ADORA2A |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; SRC |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR; PTGS1; MMP9 |
NA: NA | Upper abdominal bloating | NA | ACHE |
N00-N99: Diseases of the genitourinary system | Urinary tract infections | N39.0 | DHFR |
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1 |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53; KDR; KDR |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Renal cancer | C64 | MTOR; CA9; KDR |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR; MAPK1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; TERT; FLT3 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
A00-B99: Certain infectious and parasitic diseases | Pulmonary and extrapulmonary tuberculosis | A15-A19 | DHFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
NA: NA | Edema | NA | CA2 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |